Company

About

Chiome Bioscience

Chiome Bioscience

Tokyo, Japan

Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences. Chiome Bioscience is a clinical stage biotechnology company. Chiome's focus is on discovery and development of antibody-based therapeutics.

CogNano

CogNano

Kyoto, Japan

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

Eisai

Eisai

Tokyo, Japan

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

PURMX

PURMX

1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima 734-8553, Japan

Creation of optimal nucleic acid medicine for disease treatment with proprietary technology PURMX's solution is a drug discovery seed of small RNA nucleic acid drugs that fine-tune many target genes and deliver unprecedented therapeutic effects. PURMX already possesses a large amount of functional RNA screening data, which is being further expanded. The first stage of innovative nucleic acid medicine seeds is MIRX002. MIRX002 is a nucleic acid medicine for malignant pleural mesothelioma. We have completed non-clinical trials and are conducting investigator-initiated clinical trials at Hiroshima University Hospital starting in 2021.